Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | IGF2R | P11717 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284633 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL14783446 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL27004807 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL4009422 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL1995711 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL1931658 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL6670386 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL17554435 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL502386 | 1.00 | FBP1 (0.46) | FBP1L3MBTL1IGF2RGAATYR | |
| SCHEMBL24021536 | 0.98 | L3MBTL1 (0.46) | L3MBTL1IGF2RGAATYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281598-A1 | DNA DISPLAY OF FOLDED RNA LIBRARIES ENABLING RNA-SELEX WITHOUT REVERSE TRANSCRIPTION | BRANDEIS UNIVERSITY (US) | 2025-09-11 | — | — | US | claimed |
| CN-118028403-A | Method for synthesizing beta-nicotinamide mononucleotide by using in-vitro immobilized enzyme | 音芙医药科技(上海)有限公司 | 2024-05-14 | — | — | CN | claimed |
| US-11976273-B2 | DNA display of folded RNA libraries enabling RNA-SELEX without reverse transcription | BRANDEIS UNIVERSITY (US) | 2024-05-07 | — | — | US | claimed |
| CN-117338802-A | New use of oxidized nicotinamide adenine dinucleotide supplement | 复旦大学附属眼耳鼻喉科医院 | 2024-01-05 | — | — | CN | claimed |
| CN-116773710-A | Kit for covering metabolome and metabolic flow of multiple metabolites and use method | 清华大学 | 2023-09-19 | — | — | CN | claimed |
| WO-2022251651-A1 | DNA DISPLAY OF FOLDED RNA LIBRARIES ENABLING RNA-SELEX WITHOUT REVERSE TRANSCRIPTION | BRANDEIS UNIVERSITY (US) | 2022-12-01 | — | — | WO | claimed |
| WO-2018152470-A1 | DNA DISPLAY OF FOLDED RNA LIBRARIES ENABLING RNA-SELEX WITHOUT REVERSE TRANSCRIPTION | BRANDEIS UNIVERSITY (US) | 2018-08-23 | — | — | WO | claimed |
| CN-106834293-A | A kind of circular rna with molecular marker and its preparation method and application | 华中科技大学同济医学院附属协和医院 | 2017-06-13 | — | — | CN | claimed |
| CN-104610404-B | A kind of preparation method of ribofuranose phosphate derivative | Nantong Chang You medicine company Science and Technology Ltd. (CN) | 2016-04-06 | — | — | CN | claimed |
| CN-104610404-A | Preparation method of ribofuranose phosphate derivative | NANTONG CHANGYOU PHARMACEUTICAL TECHNOLOGY CO LTD | 2015-05-13 | — | — | CN | claimed |
| US-6329512-B1 | ISOLATING SPECIFIC OUTER MEMBRANE PROTEINS FROM HAEMOPHILUS STRAIN FROM CELL PASTE USING EXTRACTION, CONCENTRATION AND PURIFICATION STEPS; FOR INCREASING IMMUNOGENICITY OF STREPTOCOCCUS CAPSULAR POLYSACCHARIDE USED AS VACCINE | AVENTIS PASTEUR LIMITED (CA) | 2001-12-11 | — | — | US | claimed |
| US-20260146271-A1 | UDP-SUGAR BIOPRODUCTION USING MICROORGANISM HOSTS | Debut Biotechnology, Inc. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4713456-A1 | METHOD OF MODULATING RNA SPLICING | Peking University (CN) | 2026-03-25 | — | — | EP | disclosed |
| EP-4077359-B1 | GENETICALLY MODIFIED CLOSTRIDIUM STRAINS AND USES THEREOF | LIVINGMED BIOTECH S R L (BE) | 2026-03-18 | — | — | EP | disclosed |
| US-20250281598-A1 | DNA DISPLAY OF FOLDED RNA LIBRARIES ENABLING RNA-SELEX WITHOUT REVERSE TRANSCRIPTION | BRANDEIS UNIVERSITY (US) | 2025-09-11 | — | — | US | disclosed |
| EP-0427799-A1 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE. | GENSIA PHARMA (US) | 1991-05-22 | — | — | EP | disclosed |
| EP-0406408-A1 | ANTIVIRALS AND METHODS FOR INCREASING THE ANTIVIRAL ACTIVITY OF AZT | GENSIA, INC. (US) | 1991-01-09 | — | — | EP | disclosed |
| WO-1990009163-A2 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | GENSIA PHARMACEUTICALS, INC. (US) | 1990-08-23 | — | — | WO | disclosed |
| WO-1990008550-A1 | ANTIVIRALS AND METHODS FOR INCREASING THE ANTIVIRAL ACTIVITY OF AZT | GENSIA PHARMACEUTICALS, INC. (US) | 1990-08-09 | — | — | WO | disclosed |
| US-4371613-A | TRANSARABINOSYLATION USING AN ENZYME FROM BACTERIA, AN ARABINOSE DONOR AND A PURINE SOURCE | AJINOMOTO COMPANY INCORPORATED (JP) | 1983-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146271-A1 | UDP-SUGAR BIOPRODUCTION USING MICROORGANISM HOSTS | UGGT1, GALE, UGCG | FBP1 110/4885L3MBTL1 731/4885IGF2R 112/4885 |
| US-20250281598-A1 | DNA DISPLAY OF FOLDED RNA LIBRARIES ENABLING RNA-SELEX WITHOUT REVERSE TRANSCRIPTION | NSUN3, POLRMT, POLM | FBP1 3827/4885L3MBTL1 597/4885IGF2R 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.